The Johns Hopkins University earned $58 million in licensing revenue in its 2016 fiscal year, three times more than in the prior year.
Johns Hopkins Technology Ventures, the university's commercialization office, attributed the spike in part to a major sublicensing deal between one of its portfolio companies, Immunomic Therapeutics, and Japanese pharmaceutical company Astellas Pharma.